Acasti Pharma Inc Announces Positive Phase II Open Label Clinical Trial Results
Acasti Pharma Inc announced positive results for its Phase II 'randomized, open-label, dose-ranging, multi-center trial' designed to assess the safety and efficacy of its investigational new drug candidate CaPre in the treatment of mild to severe hypertriglyceridemia.
Latest Developments for Acasti Pharma Inc
Latest Key Developments in Pharmaceuticals
- Plethora Solutions Holdings PLC announces CEO Appointment
- Merck & Co Inc announces launch of new business focused on weight management interventions in U.S.
- Coronado Biosciences Inc announces management changes
- Auxilium Pharmaceuticals Inc submits application to the FDA requesting approval of xiaflex for concurrent treatment of multiple palpable cords
- Share this
- Digg this